Bryan N Paeper

6475739, Nov 5, 2002

Jul 30, 2001

09/918686

Mary E. Brunkow - Seattle WA
Sean Proll - Seattle WA
Bryan Paeper - Seattle WA

Celltech RD, Inc. - Bothell WA

C12Q 168

435 6, 435 911, 435 912, 536 243, 536 2431

The genomic locus responsible for Van Buchems disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchems disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchems disease, individuals heterozygous for and therefore carriers of Van Buchems disease, and individuals who are normal with respect to Van Buchems disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions.

6489445, Dec 3, 2002

Sep 21, 2000

09/668529

Mary E. Brunkow - Seattle WA
David J. Galas - Mercer Island WA
Brian Kovacevich - Renton WA
John T. Mulligan - Seattle WA
Bryan W. Paeper - Seattle WA
Jeffrey Van Ness - Seattle WA
David G. Winkler - Seattle WA

Celltech RD, Inc. - Bothell WA

C07K 100

530350, 530300

Compositions and methods for increasing bone density using antibodies directed to a novel class or family human of TGF- binding proteins are disclosed. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases associated with a loss of bone density, for example osteoporosis. The disclosed compositions include polypeptides, and their encoding polynucleotides, which specifically bind to at least one human bone morphogenic protein (BMP) selected from BMP-5 and BMP-6.

6495736, Dec 17, 2002

Sep 21, 2000

09/668037

Mary E. Brunkow - Seattle WA
David J. Galas - Mercer Island WA
Brian Kovacevich - Renton WA
John T. Mulligan - Seattle WA
Bryan W. Paeper - Seattle WA
Jeffrey Van Ness - Seattle WA
David G. Winkler - Seattle WA

Darwin Discovery, Ltd. - Bothell WA

A01K 67027

800 18, 800 13

A novel class or family of TGF- binding proteins is disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.

6803453, Oct 12, 2004

Sep 21, 2000

09/668021

Mary E. Brunkow - Seattle WA
David J. Galas - Mercer Island WA
Brian Kovacevich - Renton WA
John T. Mulligan - Seattle WA
Bryan W. Paeper - Seattle WA
Jeffrey Van Ness - Seattle WA
David G. Winkler - Seattle WA

Darwin Discovery Ltd. - Bothell WA

C07K 1600

53038823, 435331, 4241841, 5303871, 5303881, 5303882, 5303892

Compositions and methods for increasing bone density using antibodies directed to a novel class or family of TGF- binding proteins are provided. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases associated with a loss of bone density, for example osteoporosis.

7192583, Mar 20, 2007

Mar 6, 2003

10/384893

Mary E Brunkow - Seattle WA, US
David J Galas - Claremont CA, US
Brian Kovacevich - Renton WA, US
John T Mulligan - Seattle WA, US
Bryan W Paeper - Seattle WA, US
Jeffrey Van Ness - Claremont CA, US
David G Winkler - Seattle WA, US

Darwin Discovery Ltd. - Bothell WA

A61K 39/395

4241391, 4241331, 4241351, 4241411, 4241451, 5303879, 5303881, 53038824

Antibodies to a novel family of TGF-β binding proteins are disclosed, for use in methods of altering bone density and bone mineralization, which methods are applicable to the treatment of diseases including osteopenia and osteoporosis.

7572899, Aug 11, 2009

Mar 7, 2002

10/095248

Mary E Brunkow - Seattle WA, US
David J Galas - Claremont CA, US
Brian Kovacevich - Renton WA, US
John T Mulligan - Seattle WA, US
Bryan Paeper - Seattle WA, US
Jeffrey Van Ness - Claremont CA, US
David G Winkler - Seattle WA, US

UCB SA - Berkshire

C07H 21/04
C12N 15/00

536 231, 536 232, 4353201, 4352523, 43525411, 435325, 435419, 435 691

Nucleic acids relating to human TGF-β binding proteins are disclosed. Also disclosed are assays for selecting molecules for increasing bone mineralization and methods for utilizing such molecules.

7758858, Jul 20, 2010

Feb 27, 2004

10/788606

Mary E Brunkow - Seattle WA, US
David J Galas - Claremont CA, US
Brian Kovacevich - Renton WA, US
John T Mulligan - Seattle WA, US
Bryan W Paeper - Seattle WA, US
Jeffrey Van Ness - Claremont CA, US
David G Winkler - Seattle WA, US

Darwin Discovery Ltd. - Bothell WA

C07K 16/00
A61K 39/395
C12N 15/00

4241301, 5303871, 5303881, 53038823, 5303891, 5303892, 4241781, 435 693

Compositions and methods for increasing bone density using antibodies directed to a novel class or family of TGF-β binding proteins are provided. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases associated with a loss of bone density, for example osteoporosis.

7799523, Sep 21, 2010

Apr 3, 2003

10/408168

Bryan W. Paeper - Seattle WA, US
Sean Proll - Seattle WA, US
Patrick R. Charmley - Seattle WA, US
Mary E. Brunkow - Seattle WA, US
Andreas Gerardus Uitterlinden - Poortugaal, NL

Celltech R & D, Inc. - Bothell WA

C12Q 1/68
C12P 19/34
C07H 21/02
C07H 21/04

435 6, 435 911, 435 912, 536 231, 536 243

Compositions and methods are provided for determining in a subject a risk for having, or presence of, altered bone mineral density such as osteoporosis or osteopenia or other conditions characterized by decreased or increased bone density. Specifically, the invention relates to determination of a sclerostin gene region nucleotide polymorphism (SRP) in DNA of the sclerostin gene region of human chromosome 17. In certain embodiments, SRPs that indicate an increased risk for altered bone mineral density occur as gender-associated polymorphisms. Isolated polynucleotides comprising representative SRPs are also provided.